Clinical trials: Hair Disease
Hair Thinning
Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth using an active gummy treatment in women with self-perceived thinning hair. The main aims of this trial are: 1.
- Trial name
- NCT07224555
- Testing
- Xtressé Hair Growth Gummies
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Skin Texture Disorder, Photoaging
Safety and Efficacy Evaluation of the Mosaic Ultra Device
Evaluate the Safety and Efficacy of the Mosaic Ultra 1550nm system for the treatment of skin tone and texture, facial rejuvenation, photoaging, wrinkles, scars, stretch marks, acne vulgaris and hair loss.
- Conditions
- Skin Texture Disorder, Photoaging, Wrinkle, Scar
- Trial name
- NCT06117293
- Testing
- Mosaic
- Where
- 3 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CynosureLutronic
Androgenetic Alopecia
To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.
- Trial name
- NCT05324293
- Testing
- HMI-115
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Hope Medicine (Nanjing) Co., Ltd
Alopecia, Radiodermatitis
Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy
The study will evaluate the safety of topical norepinephrine in head and neck cancer patients who are receiving treatment with intensity modulated radiotherapy (IMRT).
- Trial name
- NCT01367990
- Testing
- Norepinephrine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- ProCertus BioPharm, Inc
Alopecia Areata
PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss.
- Trial name
- ALLEGRO-2b/3 (NCT03732807)
- Testing
- PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2
- Where
- 155 sites in United States, Argentina and 16 more
- Volunteers
- 718 people
- Sponsor
- Pfizer
Hair Disease
AGA Biocellular Stem/Stromal Hair Regenerative Study
Purpose The primary objective of this study is to evaluate the safety and efficacy of the use of a biocellular mixture of emulsified adipose-derived tissue stromal vascular fraction (AD-tSVF) and high density platelet-rich plasma…
- Trial name
- STRAAND (NCT02849470)
- Testing
- Intradermal Injection in hair loss, Platelet Rich Plasma, Adipose Derived Stem/Stromal Cells
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Healeon Medical Inc
Alopecia Areata
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03898479
- Testing
- CTP-543
- Where
- 91 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Androgenetic Alopecia
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.
- Trial name
- NCT07080931
- Testing
- 5% minoxidil foam
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Alopecia Areata
European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, severe alopecia areata.
- Trial name
- NCT05041803
- Testing
- CTP-543
- Where
- 39 sites in France, Germany and 3 more
- Volunteers
- 407 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Dermatitis, Melanoma (Skin Cancer)
Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
This study aims to determine if an artificial intelligence (AI) medical device can help doctors more accurately identify a wide variety of skin conditions and improve the efficiency of patient consultations.
- Conditions
- Dermatitis, Melanoma (Skin Cancer), Alopecia, Urticaria
- Trial name
- LegitHealthSAN (NCT07428954)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- AI Labs Group S.L
Alopecia Areata
Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
This is a multi-central, double-blind, randomized, parallel, placebo-controlled phase 3 study in adult subjects with severe alopecia areata (SALT≥50%). Approximately 330 adult patients will be enrolled into the study.
- Trial name
- NCT05470413
- Testing
- SHR0302
- Where
- 31 sites in China
- Volunteers
- 330 people
- Sponsor
- Reistone Biopharma Company Limited
Androgenetic Alopecia
Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss
In-office applied non-thermal atmospheric pressure plasma treatment on NS pretreated scalp
- Trial name
- NCT06149221
- Testing
- NTAP
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Dr. Peter C. Friedman
Telogen Effluvium
BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.
Study phase III, randomized, double-dummy, placebo controlled, single-center, of regarding the non-inferiority of the medication BL3000, when compared to Pantogar® treatment of telogen effluvium in women.
- Trial name
- NCT04880889
- Testing
- BL 3000, Reference Pantogar
- Volunteers
- 326 people
- Sponsor
- Biolab Sanus Farmaceutica
Alopecia, Androgenetic
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
- Trial name
- NCT05244980
- Testing
- TDM-105795
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Technoderma Medicines Inc.
Alopecia Areata, Alopecia
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA.
- Conditions
- Alopecia Areata, Alopecia, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT05589610
- Testing
- EQ101
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 36 people
- Sponsor
- Equillium
Alopecia; X-Rays
Radiation- Induced Alopecia in Patients Undergoing Radiation Therapy to the Brain
Study will be conducted on patients receiving Whole brain(WB) / Partial Brain(PB) radiotherapy using volumetric modulated arc therapy or intensity modulated radiotherapy at Department of Radiation Oncology, Fortis Memorial…
- Trial name
- NCT03543020
- Testing
- radiation therapy to brain
- Where
- India
- Volunteers
- 25 people
- Sponsor
- Fortis Memorial Research Institute
Androgenetic Alopecia
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
This study will assess the safety, tolerability, and efficacy of SM04554 at concentrations of 0.15% and 0.25%. Improved knowledge of the changes in hair counts and immunohistochemical analysis associated with androgenetic…
- Trial name
- NCT02503137
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Biosplice Therapeutics, Inc.
Androgenetic Alopecia, Female Pattern Baldness
Clinical Study of Probiotic Treatment for Androgenetic Alopecia
The primary objective of the study is to assess the efficacy of DA-001 as an oral supplement for treatment of female pattern hair loss.
- Trial name
- NCT06484881
- Testing
- Daniel Alain Probiotic Treatment for Androgenetic Alopecia, Topical minoxidil 5%
- Sponsor
- Applied Biology, Inc.
Alopecia, Androgenetic
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.
- Trial name
- SCALP2 (NCT05914805)
- Testing
- Clascoterone 5% solution, Vehicle solution
- Where
- 27 sites in United States, Germany and 1 more
- Volunteers
- 762 people
- Sponsor
- Cassiopea SpA
Chemotherapy-Induced Alopecia
Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia
The goal of this clinical trial is to learn if Compound 31543 (topical calcitriol) for treatment of hair-loss in patients with a diagnosis of breast cancer, gynecologic cancer or sarcomas receiving a taxane-based chemotherapy is…
- Trial name
- NCT01588522
- Testing
- Compound 31543 Calcitriol 5 μg/mL, Compound 31543 Calcitriol 10 μg/mL, Compound 31543 Calcitriol 20 μg/mL
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- BPGbio